| Patents for A61P 3 - Drugs for disorders of the metabolism (129,789) |
|---|
| 02/17/2005 | US20050038023 Inhibitors of glycogen synthase kinase-3 (gsk-3) and aurora-2, both serine/threonine protein kinases; for treating diseases such as cancer, diabetes and alzheimer's disease |
| 02/17/2005 | US20050038014 5'-carbamoyl-1,1' biphenyl-4-carboxamide derivatives and their use as p38 kinase inhibitors |
| 02/17/2005 | US20050038010 Substituted heterocyclic compounds and methods of use |
| 02/17/2005 | US20050038009 1,1-dioxo-3,3-dibutyl-5-phenyl-7-methylthio-8-(N-{(R)- alpha -[N-((S)-1-carboxypropyl) carbamoyl]-4-hydroxybenzyl}carbamoylmethoxy)-2,3,4,5-tetrahydro-1,2,5-benzothiadiazepine |
| 02/17/2005 | US20050037997 Detoxification; hydrolases or esterases; short half-life; non-insulin dependent diabetes; side effect reduction |
| 02/17/2005 | US20050037993 Bulking agents as satiety agents |
| 02/17/2005 | US20050037984 Administering protein kinase C activator |
| 02/17/2005 | US20050037971 Use of hepcidin as a regulator of iron homeostasis |
| 02/17/2005 | US20050037956 Screening method for agents useful in treating diabetes |
| 02/17/2005 | US20050037948 Calcium phosphopeptide complexes |
| 02/17/2005 | US20050037097 Pyruvate enriched onion extract |
| 02/17/2005 | US20050037095 Compositions enriched in anthocyanins |
| 02/17/2005 | US20050037077 Absorption in upper part of gastrointestinal system; microcapsules coated with hydrophilic polymer such as Eudragit |
| 02/17/2005 | US20050037069 Solid and stable creatine/citric acid composition(s) and compositions carbohydrate(s) or hydrates thereof, method for the production and use thereof |
| 02/17/2005 | US20050037009 Methods and reagents for protease inhibition |
| 02/17/2005 | US20050037005 5c8 Antigen |
| 02/17/2005 | US20050037003 Administering a soluble lymphotoxin- beta receptor, an antibody directed against LT- beta receptor, or an antibody directed against surface LT ligand with a carrier; multiple sclerosis, vision defects, psoriasis, inflammatory bowel disease; antidiabetic agents |
| 02/17/2005 | US20050036985 Use of biologically active hiv-1 tat, fragments or derivatives thereof, to target and/or to activate antigen-presenting cells, and/or to deliver cargo molecules for preventive or therapeutic vaccination and/or to treat other diseases |
| 02/17/2005 | US20050036983 In vivo use of water absorbent polymers |
| 02/17/2005 | US20050035267 Furnace mount and method of installation |
| 02/17/2005 | US20050035266 Furnace Mount and Method of Installation |
| 02/17/2005 | DE10335450A1 New N-(4-(indoline-1-sulfonyl)-phenyl)-amino acid derivatives, are peroxisome proliferator activated receptor delta activators used e.g. for treating or preventing stroke, arteriosclerosis, coronary heart disease and dyslipidemia |
| 02/17/2005 | DE10335449A1 New 2-((indoline-1-sulfonyl)-tetralinyl or indanyl)-alkanoic acid derivatives, are PPAR-delta activators useful e.g. for treating or preventing stroke, arteriosclerosis, coronary heart disease or dyslipidemia |
| 02/17/2005 | DE10335027A1 Use of telmisartan and simvastatin for treatment or prophylaxis of cardiovascular, cardiopulmonary and renal diseases e.g. hypertension combined with hyperlipidemia or atherosclerosis |
| 02/17/2005 | CA2535260A1 Method for treating cachexia with retinoid ligands |
| 02/17/2005 | CA2535066A1 Macrophage activation inhibitor |
| 02/17/2005 | CA2535026A1 Solid dispersible and/or orodispersible non-filmy containing at least one type of active substance pharmaceutical composition and method for the preparation thereof |
| 02/17/2005 | CA2534898A1 Bispecific antibodies for inducing apoptosis of tumor and diseased cells |
| 02/17/2005 | CA2534494A1 Pyrrole-based hmg-coa reductase inhibitors |
| 02/17/2005 | CA2534480A1 Novel composition comprising rosiglitazone and another antidiabetic agent |
| 02/17/2005 | CA2534471A1 Method and apparatus for producing ultrafine drug particles |
| 02/17/2005 | CA2534136A1 Indol-7 sulfonamide derivatives, their preparation and their use 5-ht-6 as modulators |
| 02/17/2005 | CA2534101A1 2-`4-(hydroxymethyl-phenylamino) -piperidine-1-yl!-n- (9h-carbazol-3-yl) - acetamine derivatives and related compounds as neuropeptide y5 (npy5) ligands for the treatment of obesity |
| 02/17/2005 | CA2534099A1 Active substance combination comprising a compound with npy receptor affinity and a compound with 5-ht6 receptor affinity |
| 02/17/2005 | CA2534098A1 Indol-4 sulfonamide derivatives, their preparation and their use 5-ht-6 as modulators |
| 02/17/2005 | CA2534096A1 2-`4(phenylamino)-piperidin-1-yl!-n-phenyl-acetamine derivatives and related compounds as neuropeptide y5 (npy5) ligands for the treatement of obesity |
| 02/17/2005 | CA2533996A1 1-sulfonylindole derivatives, their preparation and their use as 5-ht6 ligands |
| 02/17/2005 | CA2533976A1 Indol-5-yl sulfonamide derivatives, their preparation and their use 5-ht-6 as modulators |
| 02/17/2005 | CA2533970A1 Indol-6 sulfonamide derivatives, their preparation and their use 5-ht-6 as modulators |
| 02/17/2005 | CA2533463A1 2-amino-5-benzoylthiazole npy antagonists |
| 02/16/2005 | EP1506967A1 Dipeptidyl peptidase inhibitors |
| 02/16/2005 | EP1506962A2 Nitrogen-containing aromatic heterocycles |
| 02/16/2005 | EP1506951A1 Preparation and application of transhintotalphenolic acid |
| 02/16/2005 | EP1506785A1 Composition for treating or preventing hyperuricemia |
| 02/16/2005 | EP1506777A1 Obesity preventive or ameliorator containing methylidene hydrazide compound as active ingredient |
| 02/16/2005 | EP1506409A1 Assays for modulators of asparaginyl hydroxylase |
| 02/16/2005 | EP1506306A2 Nucleic acids encoding a g-protein coupled receptor involved in islet cell signaling |
| 02/16/2005 | EP1506285A2 Combinations of antibodies selective for a tumor necrosis factor-related apoptosis-inducing ligand receptor and other therapeutic agents |
| 02/16/2005 | EP1506228A2 Role of p62 in aging-related disease |
| 02/16/2005 | EP1506211A1 C-aryl glucoside sglt2 inhibitors and method |
| 02/16/2005 | EP1506200A2 Novel diazabicyclic biaryl derivatives |
| 02/16/2005 | EP1506192A1 Substituted pyrroline kinase inhibitors |
| 02/16/2005 | EP1506191A1 Benzoxazine and benzoxazinone substituted triazoles |
| 02/16/2005 | EP1506187A1 2-thio-substituted imidazole derivatives and their use in pharmaceutics |
| 02/16/2005 | EP1506186A1 Substituted heterocyclic compounds and methods of use |
| 02/16/2005 | EP1506185A1 Novel compounds and their use |
| 02/16/2005 | EP1506178A2 Bicyclic modulators of androgen receptor function |
| 02/16/2005 | EP1506015A2 Pharmaceutical combination of pde5 inhibitors with ace inhibitors |
| 02/16/2005 | EP1506011A2 An antibody selective for a tumor necrosis factor-related apoptosis-inducing ligand receptor and uses thereof |
| 02/16/2005 | EP1506003A1 Soluble formulations comprising insulin aspart and insulin detemir |
| 02/16/2005 | EP1506002A2 Treatment of crohn's disease or psoriasis using anti-inteferon gamma antibodies |
| 02/16/2005 | EP1505995A1 Chewable compositions containing a gel-forming extract of psyllium |
| 02/16/2005 | EP1505986A1 COMBINATION OF AN HMG-CoA REDUCTASE INHIBITOR AND A NITRATE ESTER |
| 02/16/2005 | EP1505984A2 Nutritional supplements and methods for prevention, reduction and treatment of radiation injury |
| 02/16/2005 | EP1505982A1 Trimegestone and estrogens for treating post menopausal disorders |
| 02/16/2005 | EP1505977A2 Administration of a partial fatty acid inhibitor such as ranolazine for the treatment of diabetes |
| 02/16/2005 | EP1505974A2 Use of compounds that are effective as selective opiate receptor modulators |
| 02/16/2005 | EP1505973A2 Methods and compositions using immunomodulatory compounds for treatment and management of cancers and other diseases |
| 02/16/2005 | EP1505968A1 Multicyclic compounds for use as melanin concentrating hormone antagonists in the treatment of obesity and diabetes |
| 02/16/2005 | EP1505967A1 Method for treating obesity |
| 02/16/2005 | EP1505965A1 Use of valsartan ot its metabolite to inhibit platelet aggregation |
| 02/16/2005 | EP1397365B1 Heteroaryl-diazabicyclo-alkanes as cns-modulators |
| 02/16/2005 | EP1296698A4 Therapeutic agents - ii |
| 02/16/2005 | EP1296697A4 Therapeutic agents - i |
| 02/16/2005 | EP1253917B1 Use of substituted 4-amino-1-phenylbutan-2-ol compounds as medicaments |
| 02/16/2005 | EP1251130B1 Fused purine derivatives |
| 02/16/2005 | EP1246814B1 Compounds and methods for modulation of estrogen receptors |
| 02/16/2005 | EP1246792A4 Compounds and compositions for delivering active agents |
| 02/16/2005 | EP1215203B1 Hydroxamic acid derivatives, process for the production thereof and drugs containing the same as the active ingredient |
| 02/16/2005 | CN2678648Y Bone protecting calcium tablet |
| 02/16/2005 | CN1582301A Peptides effective in the treatment of tumors and other conditions requiring the removal or destruction of cells |
| 02/16/2005 | CN1582285A Heteroaryl amines as glycogen synthase kinase 3beta inhibitors (GSK3 inhibitors) |
| 02/16/2005 | CN1582284A Aminopyrimidines and pyridines |
| 02/16/2005 | CN1582283A Benzothiepine ileal bile acid transport inhibitors |
| 02/16/2005 | CN1582281A Mch受体拮抗剂 Mch receptor antagonist |
| 02/16/2005 | CN1582279A Peroxisome proliferator activated receptor agonists |
| 02/16/2005 | CN1582277A Amide derivatives as glycogen synthase kinase 3-beta inhibitors |
| 02/16/2005 | CN1582276A Phenylalanine enamide derivatives |
| 02/16/2005 | CN1582275A Calcium antagonistic compound |
| 02/16/2005 | CN1582274A Inhibitors of factor Xa and other serine proteases involved in the coagulation cascade |
| 02/16/2005 | CN1582271A Inhibitors of integrin alpha v beta 6 |
| 02/16/2005 | CN1582171A Pulmonary administration of chemically modified insulin |
| 02/16/2005 | CN1582168A Combinations of sterol absorption inhibitor(s) with cardiovascular agent(s) for the treatment of vascular conditions |
| 02/16/2005 | CN1582159A Preparing material of flavanol wood lipid with increased solubility |
| 02/16/2005 | CN1582157A Rehydrating formulation |
| 02/16/2005 | CN1582151A Benzothiazepine and benzothiazepine derivatives with ileal bile acid transport (IBAT) inhibitory activity for the treatment hyperlipidaemia |
| 02/16/2005 | CN1582149A Dipeptidyl peptidase IV inhibitors and their uses for lowering blood pressure levels |
| 02/16/2005 | CN1582147A Derivatives of tryptamine and analogous compounds, and pharmaceutical formulations containing them |
| 02/16/2005 | CN1582116A 油组合物 Oil composition |
| 02/16/2005 | CN1580061A Hemin production process, and health-care composition for making iron and zinc made thereof |